The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: A novel series of CRF-1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 891-896

  Yoon, Taeyoung ^a   De Lombaert, Stéphane ^a   Brodbeck, Robbin ^a   Gulianello, Michael ^a   Chandrasekhar, Jayaraman ^a   Horvath, Raymond F ^a   Ge, Ping ^a   Kershaw, Mark T ^a   Krause, James E ^a   Kehne, John ^a   Hoffman, Diane ^a   Doller, Darío ^a   Hodgetts, Kevin J ^a  

^a NEUROGEN CORPORATION   (United States)

Author keywords

1 Aryl 4 aminoalkylisoquinoline; Anxiety; CRF 1 receptor antagonist; Depression

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; AMINO ACID; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; ISOQUINOLINE; NGD 981; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANXIETY; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DEPRESSION; DRUG DESIGN; HUMANS; ISOQUINOLINES; MOLECULAR STRUCTURE; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 38749098124     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.050     Document Type: Article

References (30)

1. Vale W., Spiess J., Rivier C., and Rivier J. Science 213 (1981) 1394
2. Holsboer F. J. Psychiatr. Res. 33 (1999) 181
3. Bale T.L., and Vale W.V. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 525
4. Spiess J., Dautzenberg F.M., Sydow S., Hauger R.L., Ruhmann A., Blank T., and Radulovic J. Trends Endocrinol. Metab. 9 (1998) 140
5. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., and De Souza E.B. Trends Pharmacol. Sci. 17 (1996) 166
6. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., and Oltersdorf T. Proc. Natl. Acad. Sci U.S.A. 92 (1995) 836
7. For recent reviews, see. Chen C. Curr. Med. Chem. 13 (2006) 1261
8. Gilligan P.J., and Li Y.-W. Curr. Opin. Drug Discov. Dev. 7 (2004) 487
9. Kehne J., and De Lombaert S. Curr. Drug Targets-CNS Neurol. Disord. 1 (2002) 467
10. Gilligan P.J., Robertson D.W., and Zaczek R. J. Med. Chem. 43 (2000) 1641
11. For some recent examples, see. Dyck B., Grigoriadis D.E., Gross R.S., Guo Z., Haddach M., Marinkovic D., McCarthy J.R., Moorjani M., Regan C.F., Saunders J., Schwaebe M.K., Szabo T., Williams J.P., Zhang X., Bozigian H., and Chen T.K. J. Med. Chem. 48 (2005) 4100
12. Lowe R.F., Nelson J., Dang T.N., Crowe P.D., Pahuja A., McCarthy J.R., Grigoriadis D.E., Conlon P., Saunders J., Chen C., Szabo T., Chen T.K., and Bozigian H. J. Med. Chem. 48 (2005) 1540
13. Hodgetts K.J., Yoon T., Huang J., Gulianello M., Kieltyka A., Primus R., Brodbeck R., De Lombaert S., and Doller D. Bioorg. Med. Chem. Lett. 13 (2003) 2497
14. Yuan J., Gulianello M., De Lombaert S., Brodbeck R., Kieltyka A., and Hodgetts K.J. Bioorg. Med. Chem. Lett. 12 (2002) 2133
15. Chen Y.L., Mansbach R.S., Winter S.M., Brooks E., Collins J., Corman M.L., Dunaiskis A.R., Faraci W.S., Gallaschun R.J., Schmidt A., and Schulz D.W. J. Med. Chem. 40 (1997) 1749
16. Schultz W.D., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Tingley III F.D., Winston E.N., Chen Y.L., and Heym J. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10477
17. Chen C., Wilcoxen K.M., Huang C.Q., Xie Y.F., McCarthy J.R., Webb T.R., Zhu Y.-F., Saunders J., Liu X.J., Chen T.K., Bozigian H., and Grigoriadis D.E. J. Med. Chem. 47 (2004) 4787
18. Chen C., Dagnino Jr. R., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.I., Liu Z., Morgan T., Webb T.R., Whitten J.P., Xie Y.F., and McCarthy J.R. J. Med. Chem. 39 (1996) 4358
19. Holsboer F. Curr. Opin. Invest. Drugs 4 (2003) 46
20. Guo Z., Tellew J.E., Gross R.S., Dyck B., Grey J., Haddach M., Kiankarimi M., Lanier M., Li B.F., Luo Z., McCarthy J.R., Moorjani M., Saunders J., Sullivan R., Zhang X., Zamani-Kord S., Grigoriadis D.E., Crowe P.D., Chen T.K., and Williams J.P. J. Med. Chem. 48 (2005) 5104
21. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.-P., and Soubrie P. J. Pharmacol. Exp. Ther. 301 (2002) 333
22. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., and Holsboer F. J. Psychiatr. Res. 34 (2000) 171
23. Kunzel H.E., Zobel A.W., Nickel T., Ackl N., Uhr M., Sonntag A., Ising M., and Holsboer F. J. Psychiatr. Res. 37 (2003) 525
24. Huang C.Q., Wilcoxen K.M., McCarthy J.R., Haddach M., Webb T.R., Gu J., Xie Y.F., Grigoriadis D., and Chen C. Bioorg. Med. Chem. Lett. 13 (2003) 3375
25. Maestro 7.0; See Schrodinger Ltd. Available from: http://www.Schrodinger.com.
26. For the synthesis of 4-amino-1-phenyl-isoquinoline see. Sawanishi H., Sashida H., and Tsuchiya T. Chem. Pharm. Bull. 33 (1985) 4564
27. Grigoriadis D.E., and De Souza E.B. Methods Neurosci. 5 (1991) 510
28. Chen C., Dagnino Jr. R., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.-I., Liu Z., Moran T., Webb T.R., Whitten J.P., Xie Y.F., and McCarthy J.R. J. Med. Chem. 39 (1996) 4358
29. Hodge C.N., Aldrich P.E., Wasserman Z.R., Fernandez C.H., Nemeth G.A., Arvanitis A., Cheeseman R.S., Chorvat R.J., Ciganek E., Christos T.E., Gilligan P.J., Krenitsky P., Scholfield E., and Strucely P. J. Med. Chem. 42 (1999) 819
30. Chaki S., Okuyama S., Nakazato A., Kumagai T., Okubo T., Ikeda Y., Oshida Y., Hamajima Y., and Tomisawa K. Eur. J. Pharmacol. 371 (1999) 205